Equity Investment

Marsi Bionics

What is Marsi Bionics?

Marsi Bionics is a company that emerged in Madrid in 2013 as a spin-off from the Centre for Automation and Robotics (CAR) of the Polytechnic University of Madrid (UPM) and the Spanish National Research Council (CSIC) to develop robotic exoskeletons with joints of variable rigidity (so that they accurately simulate muscles and tendons), to improve the human gait of patients with neuro-muscular diseases.

Marsi Bionics participates in numerous clinical trials in different hospitals and specialised centres, in addition to its laboratory, Marsi Care, where it carries out research with children and adults, to improve its designs and test their usefulness.

In addition, Marsi Bionics has Hubotik, a laboratory for analysing movement, ergonomics, biomechanics and motor control.

Marsi Bionics, as a sign of its commitment to Corporate Social Responsibility (CSR), has set up a Crowdfunding platform so that the general public can participate in treatments for children at Marsi Care.

Marsi Bionics' devices have the capacity to collect data from patients, so that once a representative sample has been collected it is stored in the cloud, allowing doctors and practitioners to personalise therapies, identify trends, draw up preliminary reports, etc. In this way, a new source of income for the company may appear in the future.

Marsi Bionics has an important competitive advantage in the market by developing its exoskeletons with patented technology that allows the adaptability of exoskeletons to the anatomy and needs of each patient.



  • MAK Active Knee: is an active knee orthosis with portable and sensorized elastic performance that is already being used commercially in rehabilitation after total knee arthroplasty. Its function is to interpret the needs of the patient and provide the strength, mobility and stability necessary to walk. This device is suitable for gait rehabilitation in patients affected by hemiplegia or weakness in the knee caused by cerebrovascular accidents (stroke), neuromuscular diseases or surgical interventions.
  • ATLAS 2030 Paediatric Exo: is the first paediatric exoskeleton on the market, designed for physical therapy of children between 4 and 10 years of age with neurological impairment (cerebral palsy, spinal cord injury, muscular atrophy and dystrophy and neuro-muscular diseases causing progressive global weakness). It is an exoskeleton composed of 8 active joints that support the child from the trunk to the feet. This exoskeleton interprets the patient's intention to move in a non-invasive way and responds to this intention at every step.

It is important to mention that the exoskeletons have been developed with variable stiffness joints (ARES technology) patented jointly by CSIC and the Universidad Politécnica de Madrid, whose use is licensed exclusively and unlimited in favour of Marsi Bionics.

Marsi Bionics actively participates in R&D projects to improve its possible designs and to make them applicable to more pathologies and ailments, extending its CE marking.

Business model

The business model developed by the company is a B2B in which exoskeletons are supplied to different hospitals and specialized centers for their application in patients, both in property and in the form of a medical device as a service (renting or payment for use).

Likewise, Marsi Bionics is evolving its MAK Active Knee device for home use without direct supervision of a physician, moving from a clinical market to mobility assistance applications in activities of daily life; thus becoming a B2C device.

What will be the destination of the funds?

Marsi Bionics will allocate the funds collected in the current Financing Round (800,000 euros) to the following items:

  • (70%) Salaries: Sales, Clinic, Engineering, Operations and Customer Services.
  • (25%) Services: clinical trials, marketing and legal expenses.
  • (3%) IT: product data platform and ERP implementation.
  • (2%) Fixed assets: IT equipment and own assembly capacity.

** Access the rest of the project tabs to download the documentation and complete your investment analysis.

Remember that you can raise your doubts and comments in the Investment Room **

Waiting list

Investment details

Fellow funders invests in this project Lead investor

Objective Assessment Report  

Objective Assessment Report

This document details the information that has been evaluated and analyzed by Fellow Funders' team of analysts (according to its own valuation and scoring models) to determine the valuation (Fair Value) of a company/project.

Objective 800.000 €


Total amount deeded in the Capital Increase registered in the Mercantile Registry.

943.920 €
Minimum ticket 1.710 €
Stakeholding price
% Equity
Partners agreement
Reference investor
Tax incentives
Guaranteed reporting period
Waiting list